Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Report from annual general meeting in OXE Marine AB (publ) on 22 May 2020

The annual general meeting resolved, among other things, the following: · The income statement and balance sheet for 2019 were adopted. The meeting resolved not to pay out dividends for the financial year 2019. The board of directors and the CEO were discharged from liability for the financial year 2019. · Reelection of board members Anders Berg, Andreas Blomdahl, Magnus Folin, Magnus Grönborg and Jon Lind and election of Mikael Mellberg as new member of the board. · Anders Berg was reappointed chairman of the board. · Remuneration to the board of directors shall be in total

Intrum increases aggregate nominal amount on existing MTN framework and publishes an updated prospectus

Intrum is today publishing an updated prospectus (in Swedish) for their Medium Term Note (MTN) programme, which enables the company to issue bonds in the Swedish market. The aggregate nominal amount for the MTN programme has been increased from SEK 5 billion to SEK 10 billion. The Swedish Financial Supervisory Authority has today approved and registered the updated prospectus. The updated prospectus can be downloaded from Intrum's website.  For further information, please contact:Emil Folkesson, Group Treasury Directortel: +46 8

Bong initiates a written procedure to obtain approval from noteholders of certain amendments to the terms and conditions of its outstanding senior notes and provides an update regarding COVID19

Bong AB (publ) (the “Company”) has today instructed Nordic Trustee & Agency AB (publ), acting in its capacity as agent (the “Agent”) for the holders of the Company’s outstanding SEK 200 million senior secured floating rate notes 2018/2021 with ISIN SE0011281419 (the “Notes”), to initiate a written procedure in accordance with the terms and conditions of the Notes. The purpose of the written procedure is to obtain the noteholders’ approval of certain amendments to the terms and conditions of the Notes. Since the issue of the Notes in October 2018 the Company and its subsidiaries (the “

SRV Group Plc's Board of Directors resolved on a rights issue and publishes the terms and conditions of the rights issue

SRV GROUP PLC      INSIDE INFORMATION       22 MAY 2020      AT 12.30 EET SRV Group Plc's Board of Directors resolved on a rights issue and publishes the terms and conditions of the rights issue NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. SRV Group Plc ("SRV") announced on 6 February 2020 that it is planning a directed share issue and a rights issue to strengthen its balance sheet. On 15 May 2020 SRV announced the

OXE Marine AB (publ) Interim report 1 January to 31 March 2020

First quarter of 2020 ·Net turnover of SEK 10.3 m (SEK 3.6 m) ·Operating Loss/EBIT of SEK -17.6 m (SEK -27.2 m) ·Net loss for the period of SEK -19.6 m (SEK -33.1 m) ·Cashflow for the period SEK 13.5 m (SEK 9.2 m) ·Earnings per share amounted to SEK -0.12 (SEK -1.12) Significant events in the First quarter ·The company name changed from Cimco Marine AB (publ) to OXE Marine AB (publ) ·The company announced its vision, mission and core values. ·Directed issue of in total 14 726 154 warrants to the European Investment Bank (“EIB”).

Ayima Group AB - Interim Report Q1

Highlights YTD Jan to Mar 2020 ·Total Revenue amounted to 33.9 MSEK (36.4) a decrease of 7% from the corresponding period in 2019, and a decrease of 2% from the previous quarter. ·Gross Profit amounted to 23.6 MSEK (26.2) a decrease of 10% from the corresponding period in 2019, but an increase of 14.9% from the previous quarter. ·A positive EBITDA result of 0.4 MSEK (0.6) a small change from the corresponding period in 2019 ·Total Comprehensive Income (after tax and exceptional items) amounted to -1.3 MSEK (-1.8) ·Operating costs amounted to 23.2MSEK (25.6)

NOTICE TO ATTEND THE ANNUAL GENERAL MEETING

The shareholders of Hemfosa Fastigheter AB (publ) ("Hemfosa") are hereby invited to the Annual General Meeting on Wednesday 24 June 2020 at 10.00 a.m. CET at SBB’s office, Strandvägen 1, Stockholm, Sweden.NOTIFICATION ETC. Shareholders who wish to attend the Annual General Meeting shall   be entered in the share register maintained by Euroclear Sweden AB on Wednesday 17 June 2020, shall   give notice of their attendance to Hemfosa no later than on Wednesday 17 June 2020. Notification shall be submitted in writing to Hemfosa Fastigheter AB (publ), "Annual General Meeting 2020", c/o

Mandatory notification of trade

Cathrine F. Torgersen, EVP Investor Relations & Communications of Norwegian Energy Company ASA ("Noreco" or “the Company”), has on 22 May 2020 purchased 700 shares in Noreco at a price of NOK 150.2643 per share. Cathrine Torgersen owns 700 shares in Noreco after the transaction and has the right to acquire or subscribe up to 20.000 additional shares in the Company, in aggregate 20.700 shares.   This information is subject of the disclosure requirements pursuant to section of 5-12 of the Norwegian Securities Trading Act  ***

Advenica Austria receives a new order for Data Diodes from a customer inside public sector

Advenica, a leading European provider of cybersecurity solutions, has received a new order for Data Diodes from a customer inside public sector.  The order is worth MSEK 1.0 and delivery is planned to Q2 2020.Advenica provides expertise and unique, technically advanced, durable and future-proof high assurance cybersecurity solutions for critical data in motion up to Top Secret classification. The company has its head office in Malmö, Sweden and established itself in Austria in mid-2017 to provide high-security cybersecurity solutions to customers in Austria and other European countries.

Open invitation to the showcasing of myFC:s hybrid vehicle concept

On June 17, myFC invites the public to a demonstration of its hybrid battery-fuel cell vehicle concept. The program will include a demonstration of the technology, a test drive, and a panel discussion.“Completing this project according to our promise to the market in the midst of a pandemic has been a challenge. I am grateful to all who made it happen,” says Michael Glantz, CEO of myFC. “I had very much looked forward to showcasing this important proof of concept at a physical event, but in light of the Covid-19 outbreak, a digital event is the responsible thing to do. We will do

Apple Pay at Conotoxia.com

Conotoxia.com customers can already use Apple Pay when paying for transactions and topping up a currency wallet. The payment method loved by Apple fans can now be selected by fintech customers, no matter what device they are using.Payment solution dedicated to Apple users has so far been available in all mobile apps enabled by Conotoxia.com. This method can now be chosen by those who prefer to use the portal’s services via Safari browser on desktop, laptop or a tablet. Apart from settling currency exchange and money transfer transactions via Apple Pay, Conotoxia.com clients can also use

CLS Conducts In-Vivo Laser Ablation Studies for Neuro and Prostate using TRANBERG Thermal Therapy System with Thermoguide and Updates Timeline for 510(k) Filing in the U.S.

Irvine, CA – May 22, 2020 - Clinical Laserthermia Systems AB  (publ) (CLS) today announced it is conducting new in-vivo precision laser ablation treatment studies for neuro and prostate using its TRANBERG Thermal Therapy System with Thermoguide  thermometry software. The company is also currently preparing its application for 510(k) clearance from the American Food and Drug Administration (FDA) for the U.S. market.  Recent dialog between CLS and the FDA has brought

NRC Group ASA initiates new share buyback program

NRC Group ASA (the "Company") has decided to initiate a new share buyback program for up to NOK 2 million in the market. The buyback program will be conducted in accordance with the authorization provided by the annual general meeting to the board of directors on 6 May 2020. Shares in the buyback will be purchased through ordinary market trades on the Oslo Stock Exchange. The program will be initiated today and terminated on 29 May 2020 at the latest. The shares purchased under this program will be used in connection with the Company's employee share program. For further

Ideagen Partners with the World Health Organisation to Support Vital Work During Coronavirus

The leading provider of governance, risk and compliance software products, Ideagen Plc, has announced a partnership with the World Health Organisation (WHO) to support its vital collaboration and policy making work with member states and other interested bodies during the coronavirus pandemic. The 73[rd] annual World Health Assembly took place earlier this week (May 18/19). In normal times there would be more than 60 items on the agenda for discussion, but this year there were only two, with the main one, unsurprisingly, being coronavirus and the global response to it.  The Assembly

INITIATOR PHARMA: 1 QUARTER REPORT 2020

Clinical progress and expanded pipelineBusiness highlights in Q1 2020 · On March 15[th] we reported the final data from the company’s Phase 2a study with IPED2015, demonstrating statistically significant and clinically relevant results on key efficacy endpoints in patients with severe ED after a single administration of IPED2015. As previously reported, the Phase 2a study was completed satisfactorily with no observations of critical adverse events.  · On March 31st we announced that we have filed a Phase 2a Clinical Trial Application (CTA) to MHRA, UK, for our candidate drug IP2018.

Q3 Interim Report January – March 2020

Opening remarks Hamlet Pharma can report significant progress during the third quarter of the financial year 2019-2020.  In February, the company raised 12.937 million SEK by issuing subscription warranties. In March, Hamlet Pharma received a major EU grant in strong international competition. The company was granted about 23 million SEK from the EIC Accelerator fund of the Horizon 2020 program. The EU grant is a signifcant quality stamp, confirming the company’s acheivements and future potential. The EU program is awarded to strengthen further clinical research, pharmaceutical

Crown Energy AB: Interim Report January-March 2020

Q1 – JANUARY-MARCH 2020 · Revenue amounted to SEK 9,108 thousand (13,046). · Operating profit amounted to SEK -5,851 thousand (3,002). · Net financial items amounted to SEK -6,186, thousand (-24,194). · Unrealised changes in property values amounted to SEK -6,186 thousand (-30,061). · Profit before tax amounted to SEK 17,549 thousand (-2,865), and profit after tax amounted to SEK 11,303 thousand (-22,239), corresponding to SEK 0.02 (-0.05). KEY EVENTS DURING REPORTING PERIOD JANUARY-MARCH 2020  ·Progress in the South African license Block 2B - Crown Energy's

Peab rebuilds E20 outside of Gothenburg

Peab has been commissioned to rebuild four kilometers of the existing stretch of E20 between Tollered and Ingared outside of Gothenburg. The road section will be turned into a highway with a speed limit of 100 kilometers per hour. The customer is the Swedish Transport Administration and the contract is worth SEK 206 million.The project includes building three interchanges along with a new combined overpass for both traffic and wild animals. In addition, Peab will build a new pedestrian and bicycle path from Tollered to Västra Bodarna. Around 23,000 vehicles a day currently travel on this

Oncopeptides completes enrollment to the pivotal phase 3 study OCEAN for relapsed refractory multiple myeloma - 450 patients included

STOCKHOLM — May 22, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces a successful completion of enrollment in the pivotal phase 3 study OCEAN for the treatment of relapsed refractory multiple myeloma. The study includes 450 patients from more than 100 hospitals around the world. Top line results are expected to be presented later this year.OCEAN is a randomized, comparative study between melflufen and pomalidomide in patients with relapsed refractory multiple myeloma (RRMM). The patients have been treated with immunomodulatory inhibitors (IMiD) and proteasome inhibitors (PI), they

Archer Limited : Archer secures multi-well P&A contract for modular rig Archer Topaz in the UKCS

Hamilton Bermuda, (May 22, 2020) Archer today announces its formal contract award for provision of modular drilling unit and associated services by TAQA. “We are delighted with the award of this contract which secures the rig work until late 2023.” said Dag Skindlo, Chief Executive Officer of Archer. Archer’s rig has been contracted by TAQA to perform a twenty-one well plug and abandonment campaign for their Northern North Sea Cormorant Alpha platform. The integrated P&A service delivery will include services provided by Archer’s Engineering, Rentals, Oiltools and Wireline

Enhertu granted Orphan Drug Designation in the US for gastric cancer

22 May 2020 07:00 BST Enhertu granted Orphan Drug Designation in the US for gastric cancer Designation follows recent US Breakthrough Therapy Designations for Enhertu for HER2-positive metastatic gastric cancer and HER2-mutant metastatic non-small cell lung cancer AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)'s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer. An estimated 27,600 new cases of gastric cancer will be diagnosed

Interim Financial Report - First quarter 2020

The first quarter (Q1) 2020 consolidated financial statements describe the operating results of SGL TransGroup International A/S (SGL Group). · The Q1 2020 revenue was DKK 1,102 million and increased by 15% vs Q1 2019. · The total Q1 2020 Gross Profit was DKK 191 million and the Gross Margin equals 17.3%. · The Q1 2020 EBITDA before special items comprise DKK 35 million; equal to an EBITDA-margin before special items of 3.2%. · For SGLT Holding II LP (SGLT Holding) Q1 revenue was USD 264 million and Adjusted EBITDA (Business performance) excluding the impact of IFRS 16 leases

There are no items matching the current filter
There are no more items matching the current filter
Back to top